Encoded Therapeutics Announces FDA Alignment, Initiation of Pivotal Study, and ASGCT Presidential Symposium Presentation of ETX101 in Dravet Syndrome

FDA alignment achieved on pivotal study design supporting a planned Biologics License Application (BLA) submission -- 30-patient pivotal study initiated, evaluating seizure reduction and ...
Precision Medicine Online

Encoded Therapeutics to Launch Pivotal Study of Dravet Syndrome Gene Therapy

In the randomized, controlled Phase III trial, children will receive either a single injection of ETX101 or be assigned to a sham control group.
Business Wire

Encoded Therapeutics Reports Clinical Progress of ETX101 Gene Therapy for Dravet Syndrome, Recaps 2024 Corporate Achievements and Provides 2025 Outlook

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Encoded Therapeutics Inc., a clinical-stage biotechnology company developing genetic medicines for severe central nervous system (CNS) disorders, today ...
Morningstar

Encoded Therapeutics Presents Positive Interim Efficacy Data from Initial Dose Levels of Phase 1/2 Trials Evaluating ETX101 Gene Therapy in Dravet Syndrome

Encoded Therapeutics Inc., a clinical-stage biotechnology company developing genetic medicines for severe neurological disorders, today announced positive interim results from its ongoing POLARIS ...
Morningstar

Encoded Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026

Encoded Therapeutics is a clinical-stage genetic medicines company developing one-time therapies for severe neurological disorders. Our vector engineering platform enables highly selective, potent, ...
MarketWatch

Encoded Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to ETX101 for the Treatment of Dravet Syndrome

Encoded Therapeutics, Inc. ("Encoded"), a clinical-stage biotechnology company developing precision genetic medicines for severe neurological disorders, today announced that the U.S. Food and Drug ...